Reflector

What to make of the simmering public and political angst

With a new Commission looming, here’s who’s vying for the top spot in shaping EU strategy, including key questions in pharma.

European industry fights over every inch on comparative drug pricing initiative.

Europe slow to action on emerging technologies, but the complex issues clouding EHRs and gene editing, for example, offer pause.

Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.

“You wanna play rough? Just try it!” was the gist of the New-Year message from the European pharma industry to the healthcare authorities circling around drug firms preparing for pricing discussions. Reflector reports.

Pair of EU meetings, while well-meant, offered little action and beg the question-what’s the true merit in working together?

The European Union is moving ahead, in its own slightly crabwise fashion, with its attempts to work out what healthcare budgets should be used for. Reflector reports.

The EMA might have expected that the publication of its plan for proactive release of clinical reports would receive a warm welcome. But, Reflector writes, it is far from a roaring success.

An escalating political debate over pharma pricing and reimbursement nears the boiling point.

Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.

Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.

The European Medicines Agency (EMA) is 20 years old this year - and it confronts many of the problems familiar to anyone at that age.

Manufacturers, wholesalers, pharmacists and even parallel importers are uniting under a common blanket, writes Reflector.

Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal

Reflector points to a number of recent alarm signals that have seen European pharma move further towards dangerous territory.

Reflector ponders recent events in the battle against counterfeit drugs.

Reflector welcomes the signs of EU agreement on encouraging the development of rare disease treatments.

Reflector casts doubt on European pharma's vision for further communication between the industry and its patients.